A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK.
Lonial S, et al. Among authors: heffner lt.
Clin Cancer Res. 2010 Oct 15;16(20):5079-86. doi: 10.1158/1078-0432.CCR-10-1662. Epub 2010 Aug 25.
Clin Cancer Res. 2010.
PMID: 20739431
Clinical Trial.